Navigation Links
QIAGEN and Max Planck Institute for Infection Biology Collaborate to Develop Assay for Active TB Risk in Individuals With Latent Infection
Date:1/9/2012

HILDEN and BERLIN, Germany, January 9, 2012 /PRNewswire/ --

  • Collaboration to create molecular test assessing a person's risk for latent TB progressing to active TB, enabling early treatment and disease outbreak prevention
  • QIAGEN strengthening its leading infectious disease portfolio with development of DNA-/RNA-based test that complements QuantiFERON-TB Gold test for latent TB
  • New assay will use whole blood transcription profiling - a new diagnostic technology developed at the Max Planck Institute's Department of Immunology
  • New molecular test to be run on the QIAsymphony modular automation platform

QIAGEN N.V. (NASDAQ: QGEN; Frankfurt: Prime Standard: QIA) and the Max Planck Institute for Infection Biology (MPIIB), Department of Immunology have announced a new collaboration to develop a molecular diagnostic test to assess the risk of an individual with latent tuberculosis (TB) developing active TB disease during their lifetime. Financial terms were not disclosed.

Approximately one-third of the world's population is estimated to be infected with Mycobacterium tuberculosis, but do not have active tuberculosis. The identification and treatment of these individuals is critical to controlling this disease since approximately 5-10% of latent TB patients are at risk for developing active TB during their lifetime, particularly those with weakened immune systems.  

As a follow-up to those who test positive for latent TB, this new test will be designed to enable early treatment before reactivation of the TB disease, when it becomes contagious and causes life-threatening respiratory illnesses and other diseases.

This new mol
'/>"/>

SOURCE QIAGEN N.V.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. QIAGEN to Develop New Companion Diagnostic for Compound in Clinical Trials for Blood Cancers
2. QIAGEN and Abbott Enter Into Agreement on Molecular Tests for HIV, HCV and HPV
3. QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics
4. QIAGEN Acquires Comprehensive Portfolio of Molecular Food Safety Tests
5. QIAGEN Acquires Exclusive Licence for Key PI3K gene
6. QIAGENs New Product Line, QIAsafe(R) DNA Blood, has Been Co-Developed With Biomatrica and is Based on Biomatricas SampleMatrix(R) Technology
7. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Second Quarter 2009 Financial Results Call Set for August 11
8. Plexus Awarded Development Contract With QIAGEN
9. QIAGEN and Chittaranjan National Cancer Institute Partner to Establish First Large-Scale Cervical Cancer Screening Program in Kolkata
10. Webcast of QIAGEN N.V.s (Nasdaq: QGEN) Fourth Quarter and Year-End 2008 Financial Results Call Set for February 10
11. QIAGEN Welcomes 3,000th Employee in 20th year of U.S. Operations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Athena Signature Series: Turning Cancer ‘Off’ – ... a professor in the Regulatory Biology Laboratory at the Salk ... points to an “off switch” for drug resistance in cancer. ... local research is making a global impact in the fight ... join host Cheryl K. Goodman, CEO of Social Global Mobile ...
(Date:11/18/2014)... American Process Inc. (Atlanta, GA) ... partnership with researchers at Georgia Institute of Technology, ... the USDA’s Forest Products Laboratory to develop ultra-strong, ... is a rapidly emerging high performance nanomaterial extracted ... to replace heavy steel structures within cars, such ...
(Date:11/18/2014)... November 18, 2014 2014 ... Industry is professional and in-depth report on ... basic information, including its definition, characterization, application, ... outline. This exploration covers the worldwide business ... industry examination covering macroeconomic environment & financial ...
(Date:11/18/2014)... Nov. 18, 2014 PDL BioPharma, Inc. (PDL) ... connection with the acquisition of Durata Therapeutics, Inc. by ... with the termination of PDL,s credit agreement with Durata, ... of $40 million, accrued interest, and prepayment and change ... a structured financing transaction with Durata in which PDL ...
Breaking Biology Technology:American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 2American Process Inc. Announces Partnership to Develop Ultra-Strong, Lightweight Automotive Components Using Nanotechnology from Nature 3PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 2PTMEG Market: 2019 Global Polytetrahydrofuran Industry Development Trends & Analysis Now at DeepResearchReports.com 3PDL BioPharma Announces Successful Conclusion of Debt Financing Agreement with Durata Therapeutics 2
... Jan. 28, 2011 Neuralstem, Inc. (Amex: ... with ReNeuron, Ltd. ending litigation between the parties.  The ... against ReNeuron in Neuralstem, Inc. v. ReNeuron, Ltd. ... pending in the United States District Court for the ...
... WASHINGTON, Jan. 27, 2011 Following are the comments ... (D-Ore.) on USDA,s announcement Thursday that the agency will ... engineered (GE) alfalfa, a key commodity in dairy farming, ... GE crop approved for widespread planting. Leahy and DeFazio ...
... Scientists have created a diamond-like lattice composed of gold ... place by strands of DNA. The structure a ... pieces known as capsids, linked by the very stuff ... scientists, ability to combine an assortment of materials to ...
Cached Biology Technology:Neuralstem, Inc. Settles Litigation Against ReNeuron, Ltd. 2USDA's Decision Thursday on Genetically Engineered Alfalfa -- Leahy and DeFazio Warn About USDA Decision Lifting All Protections for Organic and Conventional Farmers 2A mix of tiny gold and viral particles -- and the DNA ties that bind them 2
(Date:11/4/2014)... November 4, 2014   ... growth   Fuel3D , a developer of ... funding round totaling $6.4 million (£4 million). This funding builds ... earlier this year and paves the way for the commercial ... The funding round was led by Chimera Partners and ...
(Date:11/3/2014)... 3, 2014 Research and Markets has ... - Technologies, Markets and Companies" to their offering. ... and methods, which have already started to play an important ... is replacing the old fashioned bone marrow transplants. Role of ... bound to become a part of medical practice. ...
(Date:11/3/2014)... weight and preterm birth are linked to increased risk ... in the American College of Rheumatology (ACR) journal, ... weight and pre-term babies were not at greater risk ... , According to the ACR, 27 million Americans over ... Symptoms of OA range from mild to severe and ...
Breaking Biology News(10 mins):Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3Preterm, low birth-weight babies may need new hips in adulthood 2
... and the debriefing today, the Russian State Commission has given ... CEST. Today,s go-ahead marks the last milestone along the ... tiny variations in the thickness of ice floating in the ... land, the mission will provide scientists with hard evidence on ...
... of Pittsburgh provides the first identification of a human ... in products from electronics to plasticsand in laboratory tests ... to the tiny components, according to findings published online ... open the door to the use of carbon nanotubes ...
... After years of preparation and anticipation, scientists who discover ... key question about Alzheimer,s disease: Will drugs that block ... called amyloid-beta slow the progression of the devastating disease? ... Chemical & Engineering News (C&EN), ACS, weekly newsmagazine, ...
Cached Biology News:CryoSat-2 ready for launch 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 2Pitt-led study identifies human enzyme that breaks down potentially toxic nanomaterials 3
... 100 ml supplied as a 5x ... antibodies from membrane-bound proteins without destroying ... chemiluminescent or radioisotopic signals from blots. ... blots. Supplied as a 5X solution ...
...
... The Helios gene gun optimization kit ... in optimizing parameters affecting particle delivery with ... 0.25 g each of 0.6 micrometer, 1.0 ... included is a cartridge kit, that provides ...
... Tecans fully automated solution for cell ... automation for cell-line maintenance, expansion, harvesting ... system built upon standard, industry proven ... handling configuration capable of both rapid ...
Biology Products: